Clinical Data The data included:

• High anti-HBs titers: Across both the PROTECT and CONSTANT registrational Phase 3 studies, Sci-B-Vac safely elicited higher anti-HBs titers in all study subjects compared to Engerix-B, a single antigen HBV vaccine, regardless of age, gender, or underlying comorbidity.
• PROTECT study:
  • In all study subjects, adults ≥ 18 years, Sci-B-Vac induced a Geometric Mean Concentration (GMC) of anti-HBs titers that was 6x higher than that induced by Engerix-B (1,148 mIU/mL vs. 193 mIU/mL)
  • The increase was sustained across key study subgroups, where Sci-B-Vac induced GMCs of anti-HBs titers that were 4-8x higher than those induced by Engerix-B, including in older adults, diabetics, and individuals with body mass index (BMI) > 30.
• CONSTANT study:
• In all study subjects, adults age 18-45, after two vaccinations, Sci-B-Vac induced GMCs of anti-HBs titers across all three manufactured lots that were more than 7.5x higher than that induced by Engerix-B (112.5-124.1 mIU/mL vs. 14.98 mIU/mL)
• These titers increased after the third vaccination, with Sci-B-Vac inducing GMCs of anti-HBs of 4,854.9-5,979.2 mIU/mL vs. 1,526.2 mIU/mL with Engerix-B
• The e-poster data included:
  • Faster onset of seroprotection in adults age 18-45 – seroprotection rate (SPR) is defined as the percent of subjects with anti-HBs titers ≥ 10 mIU/mL:
    • In the four controlled Phase 3 studies, after two vaccinations, Sci-B-Vac achieved SPR rates of 87.2%-100% compared to 39.0%-89.4% for Engerix-B
    • In the uncontrolled Phase 4 study, Sci-B-Vac achieved a 91.9% SPR at month 2, growing to 98.8% prior to receiving the third vaccination at month 6